# Latus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/latus

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.latusbio.com/
- Total disclosed funding: $77M
- Latest round: Series A (May 4, 2026)
- Investors on record: 10

## About

Based in Philadelphia, US, and founded in 2022 and led by Peter Ghoroghchian, Latus Bio, Inc operates as a provider of therapeutics for CNS disorders. In May 2026, Latus Bio, Inc. closed USD 97 million in series A funding led by returning investor 8VC, with participation from other returning investors DCVC, Ben Franklin Technology Partners, Modi Ventures, BioAdvance, Hatch BioFund Management, and Gaingels. New investors Korea Development Bank and Helen’s Pink Sky Foundation also participated in the round. 

Latus Bio, Inc. specializes in utilizing adeno-associated virus (AAV) vectors to improve the treatment of central nervous system (CNS) disorders. The company’s technology is designed to accurately deliver therapeutic genes to specific tissues, reducing the risks of immunogenicity and toxicity commonly associated with high-dose administrations. Its program target CNS diseases such as Huntington's Disease (HD) and CLN2, provides patients with one-time gene therapies that offer meaningful reductions in toxicity and improved quality of life. 

The company plans to use the funding from May 2026 to accelerate development of its gene therapy pipeline and advance clinical programs.

## Funding rounds

- Series A, May 4, 2026, $43M — Ben Franklin Technology Partners, Korea Development Bank, BioAdvance, DCVC, 8VC, Gaingels, Hatch BioFund Management, Modi Ventures
- Series A, Nov 17, 2023, $34M — Ben Franklin Technology Partners, Samsung Venture Investment, DCVC, 8VC, Gaingels, Children's Hospital of Philadelphia Master Trust, Modi Ventures

## Investors

- Ben Franklin Technology Partners (https://capitalatlas.ai/funds/ben-franklin-technology-partners) — Series A
- Samsung Venture Investment (https://capitalatlas.ai/funds/samsung-venture-investment) — Series A
- DCVC (https://capitalatlas.ai/funds/dcvc) — Series A
- 8VC (https://capitalatlas.ai/funds/8vc) — Series A
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series A
- Children's Hospital of Philadelphia Master Trust — Series A
- Modi Ventures (https://capitalatlas.ai/funds/modi-ventures) — Series A
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series A
- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Series A
- Hatch BioFund Management (https://capitalatlas.ai/funds/hatch-biofund-management) — Series A